Analysts expect that Insulet Co. (NASDAQ:PODD) will announce $0.09 earnings per share (EPS) for the current quarter, according to Zacks. Seven analysts have provided estimates for Insulet’s earnings, with the highest EPS estimate coming in at $0.27 and the lowest estimate coming in at ($0.02). Insulet posted earnings per share of $0.16 in the same quarter last year, which would indicate a negative year over year growth rate of 43.8%. The company is scheduled to issue its next quarterly earnings report on Monday, February 24th.
According to Zacks, analysts expect that Insulet will report full-year earnings of $0.20 per share for the current year, with EPS estimates ranging from $0.09 to $0.38. For the next financial year, analysts expect that the business will post earnings of $0.70 per share, with EPS estimates ranging from $0.32 to $1.21. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Insulet.
Insulet (NASDAQ:PODD) last released its earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $192.12 million during the quarter, compared to analyst estimates of $179.50 million. Insulet had a return on equity of 9.46% and a net margin of 2.38%. The firm’s revenue for the quarter was up 27.2% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share.
Several brokerages have issued reports on PODD. UBS Group cut shares of Insulet from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $155.00 to $160.00 in a research note on Friday, October 4th. They noted that the move was a valuation call. BidaskClub cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, November 5th. ValuEngine cut shares of Insulet from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $185.00 target price (up previously from $160.00) on shares of Insulet in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group boosted their price target on shares of Insulet from $105.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. Ten investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $151.71.
PODD stock traded up $4.59 during trading on Tuesday, reaching $169.46. The company had a trading volume of 1,241,100 shares, compared to its average volume of 751,627. Insulet has a twelve month low of $70.80 and a twelve month high of $171.96. The company has a debt-to-equity ratio of 2.43, a quick ratio of 3.91 and a current ratio of 4.72. The firm has a 50-day simple moving average of $154.75 and a 200-day simple moving average of $130.77. The company has a market cap of $8.73 billion, a price-to-earnings ratio of 3,389.20 and a beta of 0.96.
In related news, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the sale, the senior vice president now directly owns 22,626 shares in the company, valued at approximately $3,306,111.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shacey Petrovic sold 649 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,491 shares of company stock worth $806,124. Corporate insiders own 3.50% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Advisors Preferred LLC purchased a new stake in Insulet in the 2nd quarter valued at about $38,000. Harvest Fund Management Co. Ltd purchased a new stake in Insulet in the 2nd quarter valued at about $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new stake in Insulet in the 2nd quarter valued at about $97,000. Steward Partners Investment Advisory LLC purchased a new stake in Insulet in the 2nd quarter valued at about $119,000. Finally, Cerebellum GP LLC purchased a new stake in Insulet in the 3rd quarter valued at about $122,000.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.